https://www.fiercebiotech.com/biotech/jpm24-roches-pharma-bd-chief-explains-renewed-adc-interest-and-invisible-bar-all-dealmaking?utm_medium=email&utm_source=nl&utm_campaign=LS-NL-FierceBiotech&oly_enc_id=9706A0310367J1T
The text below is an excerpt from the article above. Don't we have the part highlighted done and dusted
In October, Roche penned a deal potentially worth $216 million with SpliceBio for a gene therapy against an inherited retinal disease, which is Spark’s sweet spot thanks to FDA-approved Luxturna.The gene therapy world just celebrated a major breakthrough with the approval of Vertex and CRISPR Therapeutics’ Casgevy, the first gene-editing therapy based on CRISPR technology. Still, Sabry argued that the main limitation for gene therapy is the lack of ability to target specific cells effectively.
https://www.fiercebiotech.com/biotech/jpm24-roches-pharma-bd-chie...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
-0.020(1.74%) |
Mkt cap ! $659.0M | |||
| Open | High | Low | Value | Volume |
| $1.17 | $1.19 | $1.13 | $187.3K | 162.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5698 | $1.13 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.15 | 938 | 1 |
View Market Depth
| Last trade - 16.10pm 19/06/2025 (20 minute delay) ? |
| PYC (ASX) Chart |